Description: Amplia Therapeutics Limited, formerly Innate Immunotherapeutics Limited, is a pharmaceutical company. The Company is engaged in research and development of immune-oncology drugs and chemotherapies to address serious unmet needs in fibrotic tumors. The Company is focused on advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, particularly focused on pancreatic and ovarian cancer. Its initial clinical development pipeline comprises of two novel orally available small molecule FAK inhibitors: AMP945 (FAK-only) and AMP886 (FAK/FLT3/VEGFR3). FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).
Home Page: www.ampliatx.com
ATX Technical Analysis
350 Queen Street
Melbourne,
VIC
3000
Australia
Phone:
61 2 8003 3650
Officers
| Name | Title |
|---|---|
| Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D. | CEO, MD & Director |
| Mr. Hamish George | Chief Financial Officer |
| Ms. Rhiannon Jones B.Sc., Ph.D. | Chief Operating Officer |
| Ms. Terrie-Anne Cock Ph.D. | Head of Translational Biology |
| Mr. Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., LLB, MAICD | Company Sec. |
| Dr. Frank Gelder | Founding Scientist |
| Dr. James A. Taylor Ph.D. | Trials Consultant |
| Dr. Michael H. Silverman B.Sc., M.B.A., M.D., F.A.C.P., FACR | Trials Consultant |
| Dr. Benjamin M. Segal | Clinical Consultant |
| Dr. Frederick E. Reno Ph.D. | Toxicology Consultant |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9171 |
| Price-to-Sales TTM: | 5.1905 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |